Descrizione del progetto
Un miglior monitoraggio dei pazienti sottoposti a immunoterapia antitumorale
L’immunoterapia antitumorale ha contribuito notevolmente a far progredire il trattamento del cancro. Ciononostante, restano due importanti sfide che ostacolano la strada verso una migliore salute e qualità della vita per i pazienti oncologici che hanno intrapreso l’immunoterapia. Vi è la necessità di marcatori predittivi per eventi avversi legati all’immunoterapia, nonché di informazioni sui relativi pazienti al di là delle sperimentazioni controllate randomizzate. Per affrontare questi problemi, il progetto QUALITOP, finanziato dall’UE, intende sviluppare una piattaforma digitale intelligente specifica per l’immunoterapia a livello europeo. La piattaforma contribuirà a individuare i fattori determinanti dello stato di salute dei pazienti, definire i profili dei pazienti in un ambiente reale e fornire raccomandazioni in tempo reale. Il progetto consentirà quindi un miglior monitoraggio della salute e della qualità della vita dei pazienti oncologici sottoposti a immunoterapia.
Obiettivo
"Cancer immunotherapy brought about significant progress in cancer treatment. It resulted in high efficacy in some cancers; e.g. up to 60% objective response rate in melanoma and 80% complete response rate in acute lymphoblastic leukaemia. Nevertheless, two main challenges still impede improving cancer patients’ health status and quality of life (QoL) after immunotherapy initiation: 1) a crucial need for “predictive markers” of occurrence of immunotherapy-related adverse events (IR-AEs) to predict and improve patients’ health status and promote their QoL; and, 2) the lack of knowledge on patients after start of immunotherapy outside randomised controlled trials. To reach these goals, significantly more diversified sources of data are required.
Project QUALITOP aims at developing a European immunotherapy-specific open Smart Digital Platform and using big data analysis, artificial intelligence, and simulation modelling approaches. This will enable collecting and aggregating efficiently real-world data to monitor health status and QoL of cancer patients given immunotherapy. Through causal inference analyses, QUALITOP will identify the determinants of health status regarding IR-AEs and define patient profiles in a real-world context. For this, heterogeneous data sources (big data), both retrospective and prospective --collected for QUALITOP from clinical centres in four EU countries—will integrate lifestyle, genetic, and psychosocial determinants of QoL. Using machine learning approaches, QUALITOP will provide ""real-time"" recommendations stemming from patient profiles and feedbacks via the Smart Digital Platform. Furthermore, an increased visibility on patients’ behaviour, a better IR-AEs prediction, and an improvement of care coordination will help analysing through simulation modelling approaches the gain in cost-effectiveness. Guidelines will be issued over the short and long-term.
"
Campo scientifico
- natural sciencescomputer and information sciencesdata sciencebig data
- medical and health sciencesclinical medicineoncologyskin cancermelanoma
- medical and health sciencesbasic medicineimmunologyimmunotherapy
- medical and health sciencesclinical medicineoncologyleukemia
- natural sciencescomputer and information sciencesartificial intelligencemachine learning
Parole chiave
Programma(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SC1-DTH-2019
Meccanismo di finanziamento
RIA - Research and Innovation actionCoordinatore
69002 Lyon
Francia